Status:

COMPLETED

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborating Sponsors:

Genentech, Inc.

Pharmacia and Upjohn

Conditions:

Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

In this multicenter trial, we plan to evaluate the feasibility and toxicity of initial treatment with irinotecan/carboplatin/radiation therapy, followed by treatment with bevacizumab, in patients with...

Detailed Description

Upon determination of eligibility, all patients will be receive: * Irinotecan + Carboplatin + Radiation Therapy + Bevacizumab Patients will receive 4 courses of irinotecan/carboplatin. Radiation the...

Eligibility Criteria

Inclusion

  • To be included in this study, you must meet the following criteria:
  • Small cell lung cancer, confirmed by biopsy.
  • Limited stage disease after standard evaluation.
  • Able to perform activities of daily living without assistance.
  • No previous treatment with chemotherapy, radiation therapy, or biologics.
  • Measurable or evaluable disease
  • Adequate bone marrow, liver and kidney function
  • Able to understand the nature of this study and give written consent.

Exclusion

  • You cannot participate in this study if any of the following apply to you:
  • Age \< 18 years
  • History of previous malignancies
  • Women pregnant or lactating
  • History or physical exam evidence of central nervous system disease)
  • Active infection requiring intravenous antibiotics
  • Full-dose anticoagulation or thrombolytic therapy within 10 days
  • Proteinuria.
  • Serious nonhealing wound, ulcer, or bone fracture
  • Evidence if bleeding diathesis or coagulopathy
  • History of heart attack within 6 months.
  • Uncontrolled cardiovascular disease
  • PEG or G-tube
  • History of other serious disease
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Key Trial Info

Start Date :

August 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2008

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00193375

Start Date

August 1 2003

End Date

May 1 2008

Last Update

August 10 2016

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer | DecenTrialz